Payment overview · 2025
General Payments
$982.69
41 reported records · 19 companies
Healthcare provider profile · identity verified
Pardeep K Sharma, MD
Allopathic & Osteopathic Physicians|Family Medicine · COOKEVILLE, TN · NPI 1588645196
Verified facts
What the public records show
CMS Open Payments records show Pardeep K Sharma, MD received $982.69 in general payments during 2025 across 41 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $162.84 | 16.6% | 5 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $117.42 | 11.9% | 5 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $106.97 | 10.9% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $83.51 | 8.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.90 | 8.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.20 | 6.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.86 | 5.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $52.69 | 5.4% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $45.19 | 4.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.76 | 3.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $25.79 | 2.6% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $23.55 | 2.4% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.00 | 2.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.78 | 2.2% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.24 | 2.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.54 | 2.0% | 1 | 2025 |
| NxStage Medical, Inc. | Unresolved — no canonical attribution shown | $16.76 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.59 | 1.6% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $15.10 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $982.69 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $106.97 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $83.51 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.90 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.20 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.20 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $52.86 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $52.69 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $49.67 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $45.19 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.04 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.76 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $25.79 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| NXSTAGE SYSTEM ONE Normalized: nxstage system one |
Device | NxStage Medical, Inc. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $8.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 113 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 763 | 211 |
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 129 |
| Metoprolol Tartrate | Metoprolol Tartrate | 373 | 125 |
| Lisinopril | Lisinopril | 364 | 122 |
| Omeprazole | Omeprazole | 298 | 98 |
| Gabapentin | Gabapentin | 289 | 75 |
| Furosemide | Furosemide | 261 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 89 |
| Losartan Potassium | Losartan Potassium | 239 | 72 |
| Metformin Hcl | Metformin Hcl | 224 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 187 | 50 |
| Alprazolam | Alprazolam | 179 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 176 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 59 |
| Allopurinol | Allopurinol | 141 | 51 |
| Carvedilol | Carvedilol | 137 | 40 |
| Eliquis | Apixaban | 135 | 37 |
| Oxycodone Hcl | Oxycodone Hcl | 133 | 20 |
| Montelukast Sodium | Montelukast Sodium | 131 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 43 |
| Famotidine | Famotidine | 117 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 43 |
| Ozempic | Semaglutide | 113 | 33 |
| Glipizide | Glipizide | 112 | 26 |
| Metformin Hcl Er | Metformin Hcl | 109 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 40 |
| Sertraline Hcl | Sertraline Hcl | 97 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 37 |
| Glipizide Er | Glipizide | 91 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 25 |
| Clonazepam | Clonazepam | 89 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 34 |
| Meloxicam | Meloxicam | 89 | 34 |
| Simvastatin | Simvastatin | 89 | 30 |
| Atenolol | Atenolol | 88 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 33 |
| Sucralfate | Sucralfate | 82 | 42 |
| Prazosin Hcl | Prazosin Hcl | 81 | 28 |
| Chlorthalidone | Chlorthalidone | 79 | 27 |
| Potassium Chloride | Potassium Chloride | 79 | 22 |
| Diazepam | Diazepam | 78 | 15 |
| Prednisone | Prednisone | 77 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 28 |
| Pregabalin | Pregabalin | 65 | 23 |
| Novolog Flexpen | Insulin Aspart | 64 | 24 |
| Jardiance | Empagliflozin | 62 | 23 |
| Trazodone Hcl | Trazodone Hcl | 61 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 18 |
| Lovastatin | Lovastatin | 60 | 18 |
| Mounjaro | Tirzepatide | 60 | 12 |
| Fluconazole | Fluconazole | 59 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 15 |
| Azithromycin | Azithromycin | 54 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 14 |
| Lorazepam | Lorazepam | 54 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 40 |
| Mupirocin | Mupirocin | 52 | 25 |
| Spironolactone | Spironolactone | 52 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 50 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 48 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 15 |
| Benazepril Hcl | Benazepril Hcl | 46 | 14 |
| Enalapril Maleate | Enalapril Maleate | 46 | 14 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 46 | 11 |
| Nystatin | Nystatin | 46 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 12 |
| Buspirone Hcl | Buspirone Hcl | 44 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 14 |
| Memantine Hcl | Memantine Hcl | 44 | 13 |
| Trulicity | Dulaglutide | 44 | 13 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Glimepiride | Glimepiride | 41 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 14 |
| Estradiol | Estradiol | 38 | 16 |
| Ondansetron Odt | Ondansetron | 37 | 18 |
| Methylprednisolone | Methylprednisolone | 36 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 15 |
| Glyburide | Glyburide | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | 12 |
| Tramadol Hcl | Tramadol Hcl | 32 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 12 |
| Novolog | Insulin Aspart | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | 13 |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | 14 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Constulose | Lactulose | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 14 |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Zolmitriptan | Zolmitriptan | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $982.69 · 41 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CRYSVITA, CeQur Simplicity, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, FUROSCIX, GEMTESA, GVOKE HYPOPEN, Kerendia, Korlym, LOKELMA, LUPKYNIS, NXSTAGE SYSTEM ONE, Ozempic, REXULTI, Rybelsus, STRENSIQ, TAVNEOS, Veltassa | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error